Advances Toward a Norovirus Antiviral: From Classical Inhibitors to Lethal Mutagenesis

Research output: Contribution to journalJournal article – Annual report year: 2016Researchpeer-review

Without internal affiliation


  • Author: Thorne, Lucy

    University of Cambridge, United Kingdom

  • Author: Arias, Armando

    University of Cambridge

  • Author: Goodfellow, Ian G

    University of Cambridge, United Kingdom

View graph of relations

Human noroviruses are a leading cause of gastroenteritis worldwide, yet there are no licensed antivirals. There is an urgent need for norovirus therapeutics, particularly for chronic infections in immunocompromised individuals, but also a potential need for prophylactic use in epidemics. Continued research has led to the identification of compounds that inhibit norovirus replication in vitro and, at least in some cases, are also effective in vivo against murine norovirus. Progress has included classical approaches targeting viral proteins and harnessing the antiviral action of interferon, strategies targeting essential host cell factors, and novel strategies exploiting the high mutation rate of noroviruses.
Original languageEnglish
JournalJournal of Infectious Diseases
Issue numbersuppl 1
Pages (from-to)27-31
Publication statusPublished - 2016
Externally publishedYes
CitationsWeb of Science® Times Cited: No match on DOI

ID: 119955121